Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
07 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic test,...
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
03 août 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: Second quarter testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test.In the second quarter: Hereditary cancer test volumes grew 20%...
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
27 juil. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
24 juil. 2023 08h00 HE
|
Myriad Genetics, Inc.
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
06 juil. 2023 08h30 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
12 juin 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas...
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
07 juin 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will...
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
01 juin 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion...
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
31 mai 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP,...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
24 mai 2023 16h05 HE
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...